📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
4
CCCC Latest News & AI Sentiment Analysis
2 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
C4 Therapeutics (CCCC) has posted a modest 2.65% weekly gain, prompting analyst inquiry into whether the biotech stock merits...
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (NASDAQ:CCCC) 2026-06-20
C4 Therapeutics (CCCC) presented a slide deck detailing its research and development strategy around IKZF1/3 degraders for multiple...
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics (CCCC) presented a clinical transcript discussing the therapeutic landscape for multiple myeloma treatment, with...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice